LABETALOL HYDROCHLORIDE

Post-LOE

labetalol hydrochloride

Hikma

ANDAORALTABLET

Approved

Jul 1999

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LABETALOL HYDROCHLORIDE (labetalol hydrochloride) by Hikma is adrenergic beta-antagonists [moa]. Approved for hypertension, to lower blood pressure. First approved in 1999.

Drug data last refreshed 19h ago

Mechanism of Action

Adrenergic beta-Antagonists

Pharmacologic Class:

beta-Adrenergic Blocker

Indications (2)

hypertension to lower blood pressure

Worked on LABETALOL HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.